Founder and Chief Investment Officer, Casdin Capital
Eli Casdin founded Casdin Capital in 2011 after nearly 10 years spent focused on disruptive technologies and business models in life sciences and healthcare, including authoring the black book, The Dawn of Molecular Medicine.
Eli earned his B.S. from Columbia University and his MBA from the Columbia Business School. He serves on the Columbia University School of General Studies board of directors.
Casdin Capital’s combination of long-term vision and strong industry relationships keep it focused on the big picture yet nimble, while maintaining a consistent approach: Take aim at big markets; Invest in great ideas and great teams; Stay focused; Avoid hubris.
Prior to founding Casdin Capital, Eli was a vice president and analyst at Alliance Bernstein and a member of its “thematic” based investment group, responsible for researching and investing in the implications of new technologies for the life science and healthcare sectors. His early experience includes time at Bear Stearns and Cooper Hill Partners, one of the earliest biotechnology focused investment firms.
Eli serves on the board of directors for C2i Genomics, DNA Scripts, Exact Sciences, EQRx, Genomatica, the New York Genome Center, Prominex Inc, Sexton Biotechnologies and Tenaya Therapeutics. He also participates as a board observer for several early-stage therapeutic companies.
Back to Who We Are